All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What’s next in AML?
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub was pleased to speak to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked: What's next in AML?
What’s next in AML?
Amer Zeidan discusses the future directions in the management of AML, and highlights the progress that has been made in the past decade. In the US, nine novel agents have been approved for the treatment of AML over the past 3 years and here, Amer Zeidan outlines the impact he thinks these agents will have on the treatment approach to AML.
More about...
Your opinion matters
1 vote - 2 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox